Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb;9(2):e002252.
doi: 10.1136/jitc-2020-002252.

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis

Margaret Gatti-Mays  1 , James L Gulley  2
Affiliations
Editorial

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis

Margaret Gatti-Mays et al. J Immunother Cancer. 2021 Feb.
No abstract available

Keywords: guidelines as topic; immunotherapy; programmed cell death 1 receptor.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

References

    1. Puzanov I, Diab A, Abdallah K, et al. . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group. J Immunother Cancer 2017;5:95. 10.1186/s40425-017-0300-z - DOI - PMC - PubMed
    1. Nishino M, Giobbie-Hurder A, Hatabu H, et al. . Incidence of programmed cell death 1 Inhibitor-Related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2:1607–16. 10.1001/jamaoncol.2016.2453 - DOI - PubMed
    1. Michot JM, Bigenwald C, Champiat S, et al. . Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139–48. 10.1016/j.ejca.2015.11.016 - DOI - PubMed
    1. Wang DY, Salem J-E, Cohen JV, et al. . Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018;4:1721–8. 10.1001/jamaoncol.2018.3923 - DOI - PMC - PubMed
    1. Martins F, Sofiya L, Sykiotis GP, et al. . Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563–80. 10.1038/s41571-019-0218-0 - DOI - PubMed

MeSH terms

LinkOut - more resources